T
Travis S. Young
Researcher at Scripps Research Institute
Publications - 69
Citations - 4144
Travis S. Young is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Chimeric antigen receptor & Amino acid. The author has an hindex of 29, co-authored 67 publications receiving 3350 citations. Previous affiliations of Travis S. Young include Torrey Pines Institute for Molecular Studies & Scripps Health.
Papers
More filters
Journal ArticleDOI
An enhanced system for unnatural amino acid mutagenesis in E. coli.
TL;DR: A new vector, pEVOL, for the incorporation of unnatural amino acids into proteins in Escherichia coli using evolved Methanocaldococcus jannaschii aminoacyl-tRNA synthetase (aaRS)/suppressor tRNA pairs is reported.
Journal ArticleDOI
Coordinated Regulation of Accessory Genetic Elements Produces Cyclic Di-Nucleotides for V. cholerae Virulence
TL;DR: This pathway couples the actions of previously disparate genomic islands, defines VSP-1 as a pathogenicity island in V. cholerae, and implicates its occurrence in 7(th) pandemic strains as a benefit for host adaptation through the production of a regulatory cyclic di-nucleotide.
Journal ArticleDOI
Beyond the Canonical 20 Amino Acids: Expanding the Genetic Lexicon
Travis S. Young,Peter G. Schultz +1 more
TL;DR: The ability to genetically encode unnatural amino acids beyond the common 20 has allowed unprecedented control over the chemical structures of recombinantly expressed proteins.
Journal ArticleDOI
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
David T. Rodgers,Magdalena Mazagova,Eric Hampton,Yu Cao,Nitya S. Ramadoss,Ian R. Hardy,Andrew D Schulman,Juanjuan Du,Feng Wang,Oded Singer,Jennifer S. Y. Ma,Vanessa Núñez,Jiayin Shen,Ashley K. Woods,Timothy M. Wright,Peter G. Schultz,Chan Hyuk Kim,Travis S. Young +17 more
TL;DR: It is shown that switches specific for CD19 govern the activity, tissue-homing, cytokine release, and phenotype of switchable CAR-T cells in a dose-titratable manner using xenograft mouse models of B-cell leukemia.
Journal ArticleDOI
Versatile strategy for controlling the specificity and activity of engineered T cells.
Jennifer S. Y. Ma,Ji Young Kim,Stephanie A. Kazane,Sei-hyun Choi,Hwayoung Yun,Min Soo Kim,David T. Rodgers,Holly Pugh,Oded Singer,Sophie B. Sun,Bryan R. Fonslow,James N. Kochenderfer,Timothy M. Wright,Peter G. Schultz,Travis S. Young,Chan Hyuk Kim,Yu Cao +16 more
TL;DR: It is demonstrated that a switch-mediated CAR-T approach enables the titration of engineered T-cell antitumor activity, which was observed to be highly advantageous in reducing treatment-related toxicities in vivo.